AMRX [NYSE]
Amneal Pharmaceuticals, Inc.
Index- P/E314.00 EPS (ttm)0.01 Insider Own1.60% Shs Outstand149.89M Perf Week-13.26%
Market Cap1.03B Forward P/E3.49 EPS next Y0.90 Insider Trans0.00% Shs Float118.21M Perf Month-0.95%
Income1.80M PEG- EPS next Q0.22 Inst Own67.80% Short Float2.88% Perf Quarter-5.71%
Sales2.10B P/S0.49 EPS this Y155.00% Inst Trans-0.16% Short Ratio4.95 Perf Half Y-32.91%
Book/sh2.61 P/B1.20 EPS next Y16.91% ROA0.30% Target Price5.90 Perf Year-38.31%
Cash/sh0.64 P/C4.92 EPS next 5Y-12.10% ROE2.90% 52W Range2.90 - 5.99 Perf YTD-34.45%
Dividend- P/FCF4.34 EPS past 5Y15.00% ROI4.50% 52W High-51.25% Beta1.19
Dividend %- Quick Ratio1.50 Sales past 5Y20.50% Gross Margin36.90% 52W Low0.69% ATR0.19
Employees7000 Current Ratio2.30 Sales Q/Q0.90% Oper. Margin7.30% RSI (14)34.79 Volatility7.84% 5.44%
OptionableYes Debt/Eq7.17 EPS Q/Q-132.40% Profit Margin0.50% Rel Volume3.68 Prev Close3.14
ShortableYes LT Debt/Eq7.09 EarningsAug 05 BMO Payout0.00% Avg Volume688.05K Price2.92
Recom2.40 SMA20-12.47% SMA50-11.65% SMA200-28.86% Volume2,533,712 Change-7.01%
Apr-07-21Resumed RBC Capital Mkts Sector Perform $5
Mar-08-21Upgrade Goldman Sell → Buy $4 → $6.50
Dec-14-20Upgrade Guggenheim Neutral → Buy $5.50
Dec-14-20Upgrade Barclays Equal Weight → Overweight $4.50 → $6
Jul-27-20Initiated Goldman Sell $4
May-12-20Upgrade Guggenheim Sell → Neutral
Dec-12-19Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19Downgrade JP Morgan Neutral → Underweight
Nov-07-19Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19Upgrade SVB Leerink Mkt Perform → Outperform $11 → $5
Jul-11-19Downgrade RBC Capital Mkts Outperform → Sector Perform $11 → $6
Jul-08-19Upgrade Piper Jaffray Neutral → Overweight
Jun-11-19Initiated Barclays Equal Weight $9
May-21-19Upgrade Raymond James Mkt Perform → Strong Buy $13
Mar-20-19Initiated SunTrust Buy $16
Mar-08-19Downgrade SVB Leerink Outperform → Mkt Perform $16 → $12
Dec-14-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-16-18Downgrade SunTrust Buy → Hold
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-23-18Initiated Morgan Stanley Overweight $22
Aug-11-22 04:05PM  
Aug-08-22 09:37AM  
Aug-05-22 08:16AM  
07:25AM  
06:00AM  
Aug-03-22 08:00AM  
Jul-12-22 07:26AM  
Jul-08-22 08:00AM  
Jun-07-22 08:00AM  
Jun-01-22 08:00AM  
May-27-22 06:00AM  
May-24-22 08:00AM  
May-18-22 07:05AM  
May-13-22 08:00AM  
May-04-22 07:25AM  
06:00AM  
Apr-13-22 04:01PM  
Apr-07-22 08:00AM  
Mar-24-22 08:00AM  
Mar-21-22 04:34PM  
Mar-17-22 04:05PM  
Mar-02-22 07:25AM  
06:00AM  
Mar-01-22 04:05PM  
Feb-23-22 03:00PM  
Feb-17-22 08:00AM  
Feb-04-22 09:40AM  
08:00AM  
Feb-02-22 04:47AM  
Jan-28-22 09:35AM  
Jan-05-22 06:05AM  
Dec-21-21 08:00AM  
Dec-19-21 06:13AM  
Dec-17-21 05:15PM  
Nov-19-21 08:00AM  
Nov-12-21 08:00AM  
05:37AM  
Nov-03-21 04:01PM  
07:25AM  
06:00AM  
Nov-02-21 08:00AM  
Oct-29-21 03:00PM  
Oct-27-21 08:00AM  
Oct-25-21 12:10PM  
Oct-10-21 08:01AM  
Oct-06-21 08:00AM  
Sep-07-21 08:00AM  
Aug-26-21 11:04AM  
05:52AM  
Aug-25-21 04:01PM  
Aug-23-21 08:00AM  
Aug-11-21 01:24AM  
Aug-09-21 01:30PM  
07:25AM  
06:00AM  
Aug-04-21 09:34AM  
Aug-02-21 03:01PM  
Jul-25-21 06:20PM  
Jul-19-21 04:32PM  
Jul-15-21 08:00AM  
Jul-07-21 11:40AM  
Jun-17-21 10:31AM  
08:00AM  
Jun-07-21 08:00AM  
May-14-21 09:00AM  
May-10-21 11:40AM  
May-07-21 06:00PM  
07:30AM  
06:45AM  
06:00AM  
Apr-30-21 03:00PM  
Apr-15-21 08:00AM  
Apr-12-21 08:15AM  
Apr-09-21 01:32AM  
Apr-05-21 08:00AM  
Mar-31-21 11:50AM  
Mar-15-21 04:08PM  
Mar-08-21 09:51AM  
Mar-01-21 10:39AM  
Feb-26-21 06:30PM  
07:30AM  
06:30AM  
06:02AM  
Feb-25-21 10:04AM  
Feb-22-21 04:05PM  
Feb-10-21 11:40AM  
Feb-09-21 12:10PM  
Feb-07-21 11:32PM  
Feb-04-21 08:00AM  
Jan-15-21 11:40AM  
Jan-12-21 06:00AM  
Jan-08-21 08:00AM  
Jan-05-21 09:23AM  
Dec-16-20 01:57PM  
Dec-11-20 10:00PM  
Nov-23-20 10:24AM  
Nov-16-20 09:45AM  
Nov-11-20 08:35AM  
Nov-10-20 05:09AM  
Nov-06-20 09:30PM  
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel GautamDirectorDec 17Buy4.2150,000210,500258,784Dec 20 06:49 PM
Patel ChintuCo-CEODec 16Buy4.2550,000212,500512,566Dec 17 04:15 PM
Patel Chirag K.President & Co-CEODec 16Buy4.2550,000212,500512,566Dec 17 04:15 PM
Patel Chirag K.President & Co-CEODec 15Buy4.13100,000413,000462,566Dec 17 04:15 PM
Patel ChintuCo-CEODec 15Buy4.13100,000413,000462,566Dec 17 04:15 PM
Shah NikitaExecutive Vice PresidentDec 15Sale3.952,0007,900212,996Dec 17 04:15 PM
Todisco JosephExecutive Vice PresidentDec 02Sale4.101,5006,150281,319Dec 03 06:19 PM